Two flavonoid senolytics — Mayo Clinic pilot vs Dasatinib adjunct
What this is
Head-to-head evidence table: Fisetin vs Quercetin (compound).
Why it matters
Fisetin and quercetin are both flavonoids studied for senolytic activity — the ability to selectively eliminate senescent "zombie" cells that accumulate with age and drive inflammaging. They share the BCL-2/BCL-XL inhibition pathway but differ dramatically in their human evidence, dosing strategy, and solo OTC viability. Fisetin has a standalone Mayo Clinic phase 1 pilot; quercetin is most studied in combination with the prescription drug dasatinib (D+Q protocol).
What to do next
Use the verdict row to pick a primary compound, then open both deep-dives and /shop verification checklists.
Fisetin and quercetin are both flavonoids studied for senolytic activity — the ability to selectively eliminate senescent "zombie" cells that accumulate with age and drive inflammaging. They share the BCL-2/BCL-XL inhibition pathway but differ dramatically in their human evidence, dosing strategy, and solo OTC viability. Fisetin has a standalone Mayo Clinic phase 1 pilot; quercetin is most studied in combination with the prescription drug dasatinib (D+Q protocol).
Standalone senolytic human evidence
Quercetin alone has not shown clinically significant senolytic effect in RCTs
Fisetin
Phase 1 feasibility (Trivedi 2019): cleared circulating senescent cells in 14 subjects
Quercetin
Weak as solo agent — primarily studied as D+Q adjunct
Prescription pairing
If physician prescribes Dasatinib, Quercetin is the validated pairing — not Fisetin
Fisetin
Used as OTC standalone or with physician-guided protocol
Quercetin
Synergistic with Dasatinib (BCR-ABL inhibitor); D+Q is the benchmark senolytic regimen
Neurological evidence
Fisetin
Strong preclinical: BDNF upregulation, reduces tau, neuroinflammation in aged mice
Quercetin
Moderate — primarily anti-inflammatory, less direct neuroproliferative data
AMPK / metabolic support
Fisetin
Minor AMPK signal; not primary mechanism
Quercetin
Quercetin activates AMPK and has modest MetS data
Bioavailability
Both are poor without formulation optimization; quercetin dihydrate + piperine preferred
Fisetin
Poor native — requires fat co-ingestion; isorhamnetin metabolite is active form
Quercetin
Quercetin-3-glucoside better absorbed; piperine co-administration boosts plasma levels
Dosing strategy
Fisetin
Pulse dosing: 20 mg/kg body weight for 2 consecutive days, repeat monthly
Quercetin
D+Q: 100 mg dasatinib + 1,000 mg quercetin on same 2-day pulse schedule
OTC accessibility
Fisetin
Widely available; Fisetin 100–500 mg capsules from reputable suppliers
Quercetin
Quercetin OTC but Dasatinib is Rx-only — limiting the validated protocol
Safety profile
Compare quercetin safety only — adding dasatinib significantly changes risk profile
Fisetin
Excellent — no serious adverse events at doses up to 1,200 mg in pilot
Quercetin
Quercetin itself is safe; Dasatinib carries cardiovascular and pleural effusion risk
TNiC verdict
Fisetin is the stronger OTC-only senolytic choice: the only flavonoid with a standalone Mayo Clinic clinical signal. Quercetin belongs in a D+Q protocol (physician supervised) — solo OTC quercetin has weak senolytic evidence. Do not replace dasatinib with quercetin for serious senolytic intent.
Choose Fisetin when
Choose Quercetin when